|
 |
|
|||||||
|
|||||||||
Diabetes 52:838-845, 2003
© 2003 by the American Diabetes Association, Inc.
Role of Protein Kinase C on the Expression of Platelet-Derived Growth Factor and Endothelin-1 in the Retina of Diabetic Rats and Cultured Retinal Capillary Pericytes
1 Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts
2 Department of Pathology, School of Medicine University of Washington, Seattle, Washington
Increased expression of endothelin-1 (ET-1) is associated with diabetic retinopathy and vasculopathy, although the molecular explanation has not been defined. The effects of high glucose and protein kinase C (PKC) activation on platelet-derived growth factor (PDGF)-BB and of ET-1 expression in the retina of streptozotocin (STZ)-induced diabetic rats and bovine retinal pericytes (BRPC) were examined. In 4-week diabetic rats, PDGF-B and prepro-ET-1 (ppET-1) mRNA levels increased significantly by 2.8- and 1.9-fold, respectively, as quantified by RT-PCR. Treatment with PKC-ß isoform–specific inhibitor (LY333531) or insulin normalized retinal ET-1 and PDGF-B expression. In BRPC, high glucose levels increased ppET-1 and PDGF-B mRNA expression by 1.7- and 1.9-fold, respectively. The addition of PDGF-BB but not PDGF-AA increased expression of ppET-1 and vascular endothelial growth factor mRNA by 1.6- and 2.1-fold, respectively, with both inhibited by AG1296, a selective PDGF receptor kinase inhibitor. A general PKC inhibitor, GF109203X, suppressed PDGF-BB’s induction of ET-1 mRNA. Thus, increased ET-1 expression in diabetic retina could be due to increased expression of PDGF-BB, mediated via PDGF-ß receptors in part by PKC activation. The novel demonstration of elevated expression of PDGF-B and its induction by PKC activation identifies a potential new molecular step in the pathogenesis of diabetic retinopathy.
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. Ohshiro, R. C. Ma, Y. Yasuda, J. Hiraoka-Yamamoto, A. C. Clermont, K. Isshiki, K. Yagi, E. Arikawa, T. S. Kern, and G. L. King Reduction of Diabetes-Induced Oxidative Stress, Fibrotic Cytokine Expression, and Renal Dysfunction in Protein Kinase C{beta}-Null Mice Diabetes, November 1, 2006; 55(11): 3112 - 3120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Masuzawa, S. Jesmin, S. Maeda, S. Zaedi, N. Shimojo, T. Miyauchi, and K. Goto Effect of endothelin dual receptor antagonist on VEGF levels in streptozotocin-induced diabetic rat retina. Experimental Biology and Medicine, June 1, 2006; 231(6): 1090 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Barbuch, K. Campanale, C. E. Hadden, M. Zmijewski, P. Yi, D. D. O'Bannon, J. L. Burkey, and P. Kulanthaivel IN VIVO METABOLISM OF [14C]RUBOXISTAURIN IN DOGS, MICE, AND RATS FOLLOWING ORAL ADMINISTRATION AND THE STRUCTURE DETERMINATION OF ITS METABOLITES BY LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY AND NMR SPECTROSCOPY Drug Metab. Dispos., February 1, 2006; 34(2): 213 - 224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. V Joy, A. C Scates, S. Bearelly, M. Dar, C. A Taulien, J. A Goebel, and M. J Cooney Ruboxistaurin, a Protein Kinase C {beta} Inhibitor, as an Emerging Treatment for Diabetes Microvascular Complications Ann. Pharmacother., October 1, 2005; 39(10): 1693 - 1699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. I. Savage, J. W. Hendrix, D. C. Peterson, H. Young, and C. P. Wilkinson Differences in Pulsatile Ocular Blood Flow among Three Classifications of Diabetic Retinopathy Invest. Ophthalmol. Vis. Sci., December 1, 2004; 45(12): 4504 - 4509. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |